$CTXR “Lion Stock Alerts” Promoter Rank: 28/31 Citius Pharmaceuticals Inc. Newsletter 7:33:42 AM September 16, 2020

on September 16, 2020 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Lion Stock Alerts"

The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":

11%

1 out of 9 campaigns closed down on first day

33%

3 out of 9 campaigns closed up on first day

55%

5 out of 9 campaigns had no net effect

CTXR Promotional Newsletter

The following is a newsletter released by "Lion Stock Alerts" promoting Citius Pharmaceuticals Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

LionStockAlerts

Don't Want Anymore Emails

Hello

New Trade Alert Citius Pharmaceuticals, Inc. NASDAQ CTXR

CTXR has presented you with several incredible opportunities this year that we have highlighted to you.

We first alerted CTXR in December when it was trading at just 0.60, after which it rallied to a high of 1.97 in June, experiencing total upside of more than 228%.

Since our last update, CTXR has released several developments and could present the company with continued growth potential.

As a reminder, CTXR is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products.

The company focuses on anti-infectives and cancer care.

The companys strategy is unique whereby it uses innovative, patented, or proprietary formulations of previously-approved active pharmaceutical ingredients.

Furthermore, CTXR develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches.

CTXR is leveraging the FDAs 505b2 pathway for new drug approvals to bring products to market faster and with lower cost than other FDA new drug approval pathways.

Specifically, this method helps avoid unnecessary duplication of studies already performed on previously approved drugs.

In addition, CTXR is currently advancing three proprietary product candidates into large markets that are underserved by the current standards of care.

Mino-Lok, which is in FDA Phase III trials, is the companys lead product and is an antibiotic lock solution for use to treat cancer patients or hemodialysis patients with catheter-related bloodstream infections CRBSIs.
Mino-Wrap or CITI-101, which is pre-clinical, is a bio-absorbable film impregnated with minocycline and rifampin used to prevent post-surgical infections and reduce microbial colonization of breast tissue expanders used in breast reconstruction following mastectomies.
Halo-Lido or CITI-002, which is in FDA Phase II trials, is being developed for symptomatic relief of hemorrhoids and combines the high-potency steroid halobetasol with lidocaine.

In addition, earlier this year the company announced

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome ARDS Associated with COVID-19

In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program CTAP to accelerate the development of treatments for COVID-19.

In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Since our last update, the company has announced several breaking developments that could be additional growth catalysts.

In July, the company announced

Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer CMO and Executive Vice President
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19

In August, the company announced

Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

Recently, the company announced

Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap

Expansion of patents granted to The University of Texas System on behalf of M. D. Anderson Cancer Center

Here are the companys comments from this press release

The frequency of post-mastectomy breast reconstruction, following breast cancer treatment, has been increasing on an annual basis. There are over 100,000 patients in the U.S. undergoing breast reconstruction procedures following mastectomies and approximately 80% of the time, a TE is used to prepare the surgical site for breast implants either immediately after mastectomy or in a separate procedure afterwards. The published rate of infection for TEs used in breast reconstructive surgery is between 2.5 % and 24%, with an estimated mean at around 12% to 14%. These data points are concerning and not well understood. Through our agreement with MDACC, we believe Mino-Wrap has the potential to provide a significant reduction in the incidence of infection, sparing the patient the pain and discomfort of extended hospitalization and further aggressive and lengthy courses of antibiotics in an attempt to salvage the TEs. In many cases the TE is removed leading to a delay in lifesaving chemo-radiation therapy, which can be a devastating consequence for the patient. said Myron Holubiak, President and CEO of Citius Pharmaceuticals. We are especially pleased that the claims for Mino-Wrap intellectual property are being expanded and broadened as we develop the optimal design and application.

In addition, yesterday the company announced

Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance

Here is the companys summary from this press release

Mino-Lok trial continues to progress despite challenges of conducting clinical trials in COVID-stressed sites
Interim efficacy review with Drug Monitoring Committee planned for end of this month

CTXR could present continued growth potential.

Make sure to do your own due diligence.

Sources , , , , , , , , , , , , , ,

Happy Trading

LionStockAlerts

Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.

Trading Rules Please Review Before Taking Any Action
Do not invest more than you are willing to lose. No one likes to consider the worst case, but its always a risk that exists. Rule of thumb - if you cannot sleep at night as a consequence of your investment, then you have over invested.
Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use trailing stop % or trailing stop $ orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
Cut losses quickly when dayswing trading. It's better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
Actively manage all your investments trade during market hours only.Trading during prepost market hours carries greater volatilityrisk.

--------------------------

DISCLAIMER

This reportrelease is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list. The track record, gains, upside, andor losses mentioned are all hypothetical and should not be considered as the basis for investment. While we do not charge for the SMS service, standard carrier message and data rates may apply.

This reportrelease is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Reportsreleases distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should read and review, if and to the extent available, any information concerning a marketed company available at the web sites of the U.S. Securities and Exchange Commission the SEC atthe Financial Industry Regulatory Authority the FINRA at and your State Securities Administrator. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at , as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of 1 an client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in our disseminated reportsreleases is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned here.

LionStockAlerts.com is compliant with the Can Spam Act of 2003. LionStockAlerts.com does not offer such advice or analysis, and LionStockAlerts.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

We have not determined if the statements and opinions of the message are accurate, correct or truthful. The profiles we publish are compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because virtually all information relied upon by us in preparing an Issuer profile comes from a public source which has been made public directly from the Issuer, the information is not confirmed with a second source.

The purpose of this reportrelease, like any promotion, is to provide publicity for the client company, its products or services. Owners and operators of LionStockAlerts.com have been compensated twenty five thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 91120. Previously, owners and operators of LionStockAlerts.com have been compensated fifteen thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 8320. Previously, owners and operators of LionStockAlerts.com have been compensated twenty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 7220. Previously, owners and operators of LionStockAlerts.com have been compensated eighteen thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 52920. Previously, owners and operators of LionStockAlerts.com have been compensated twenty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 42320. Previously, owners and operators of LionStockAlerts.com have been compensated twenty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 32720. Previously, owners and operators of LionStockAlerts.com have been compensated ten thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 31020. Previously, owners and operators of LionStockAlerts.com have been compensated five thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 13020. Previously, owners and operators of LionStockAlerts.com have been compensated ten thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 12220. Previously, owners and operators of LionStockAlerts.com have been compensated fifteen thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 121619. Previously, owners and operators of LionStockAlerts.com have been compensated twenty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 12318. Previously, owners and operators of LionStockAlerts.com have been compensated thirty five thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Venado Media on 92818. Previously, owners and operators of LionStockAlerts.com have been compensated twenty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR by Sunrise Media on 101017. Previously owners and operators of LionStockAlerts.com have been compensated ten thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for CTXR from Third Coast Media on 72616. Owners and operators of LionStockAlerts.com hold no stocks or bonds in mentioned companies as of 91620. You should not rely on the information presented you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.

You are receiving this reportrelease because you subscribed to receive it at our website or through a third party site. All of our newsletters include an unsubscribe link, and you can remove yourself at any time from our newsletters by clicking on that unsubscribe link. You can also contact us at infoLionStockAlerts.com to change your information at any time. By your subscription to our profiles, the viewing of this profile andor use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be read at any time at www.LionStockAlerts.comDisclaimer and www.LionStockAlerts.comPrivacy-Policy

The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.

6020 Bent Pine Drive
Orlando FL 32828
USA